Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Experience with Emicizumab Among People with Hemophilia A in the Canadian Hemophilia Bleeding Disorders Registry

Man-Chiu Poon, Adrienne Lee, Federico Germini, Arun Keepanasseril, Quazi Ibrahim, Letizia Polito, Katya Moreno, Michelle Santos, Emma Iserman, Davide Matino, Alfonso Iorio

Blood (2023) 142 (Supplement 1): 1240.

https://doi.org/10.1182/blood-2023-174057

Published: 2023

Journal Articles

Real-World Outcomes of Emicizumab in Hemophilia A with or without FVIII Inhibitors from the Canadian Hemophilia Bleeding Disorder Registry

Man-Chiu Poon, Adrienne Lee, Federico Germini, Arun Keepanasseril, Quazi Ibrahim, Francis Nissen, Katya Moreno, Michelle Santos, Emma Iserman, Davide Matino, Alfonso Iorio

Blood (2022) 140 (Supplement 1): 8465–8467.

https://doi.org/10.1182/blood-2022-157531

Published: 2022

Journal Articles

Emicizumab Outcomes in Hemophilia A Using Real-World Data from the Canadian Hemophilia Bleeding Disorder Registry

Man-Chiu Poon, Adrienne Lee, Federico Germini, Arun Keepanasseril, Quazi Ibrahim, Francis Nissen, Fabian Sanabria, Michelle Santos, Emma Iserman, Davide Matino, Alfonso Iorio

Blood (2021) 138 (Supplement 1): 347.

https://doi.org/10.1182/blood-2021-147195

Published: 2021

Journal Articles

Not All Patients Benefit from Switching to Ehl: Results from the Wapps Database

Olav Versloot, MSc, Emma Iserman, Pierre Chelle, PhD, Federico Germini, MD MSc, Tushara Mathew, Alfonso Iorio, MDPhD, Kathelijn Fischer

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-142816

Published: 2020

Journal Articles

Terminal Half-Life of Factor VIII/IX According to Age and Blood Group Based on 8550 Assessments

Olav Versloot, MSc, Emma Iserman, Pierre Chelle, PhD, Federico Germini, MD MSc, Tushara Mathew, Alfonso Iorio, MDPhD, Kathelijn Fischer

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-141801

Published: 2020

Journal Articles

Developing a Two-Sided Intervention To Facilitate Shared Decision Making In Haemophilia: Decision Boxes For Clinicians and Brief Patient Decision Aids For Patients

Abha Athale, B.ASc, Anik Giguere, PhD, Angela Barbara, PhD, MSc, Emma Iserman, Alfonso Iorio, MD, PhD

Blood (2013) 122 (21): 1748.

https://doi.org/10.1182/blood.V122.21.1748.1748

Published: 2013

NARROW

Experience with Emicizumab Among People with Hemophilia A in the Canadian Hemophilia Bleeding Disorders Registry

Real-World Outcomes of Emicizumab in Hemophilia A with or without FVIII Inhibitors from the Canadian Hemophilia Bleeding Disorder Registry

Emicizumab Outcomes in Hemophilia A Using Real-World Data from the Canadian Hemophilia Bleeding Disorder Registry

Not All Patients Benefit from Switching to Ehl: Results from the Wapps Database

Terminal Half-Life of Factor VIII/IX According to Age and Blood Group Based on 8550 Assessments

Developing a Two-Sided Intervention To Facilitate Shared Decision Making In Haemophilia: Decision Boxes For Clinicians and Brief Patient Decision Aids For Patients

Email alerts

ASH Publications

American Society of Hematology

Experience with Emicizumab Among People with Hemophilia A in the Canadian Hemophilia Bleeding Disorders Registry

Real-World Outcomes of Emicizumab in Hemophilia A with or without FVIII Inhibitors from the Canadian Hemophilia Bleeding Disorder Registry

Emicizumab Outcomes in Hemophilia A Using Real-World Data from the Canadian Hemophilia Bleeding Disorder Registry

Not All Patients Benefit from Switching to Ehl: Results from the Wapps Database

Terminal Half-Life of Factor VIII/IX According to Age and Blood Group Based on 8550 Assessments

Developing a Two-Sided Intervention To Facilitate Shared Decision Making In Haemophilia: Decision Boxes For Clinicians and Brief Patient Decision Aids For Patients

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only